August 29, 2018
FDA proposes not including three bulk drug substances that outsourcing facilities may use in compounding
Editor's Note
The Food and Drug Administration (FDA) on August 28 issued a notice proposing not to include three bulk FDA-approved drug substances−bumetanide, nicardipine hydrochloride, and vasopressin−on the list that outsourcing facilities may use in compounding drug products.
The FDA is seeking public comment before finalizing their decision. Comments must be received by October 29, 2018.
Free Daily News
- Healthcare employment up in December
- Hospital M&A trends report reveals financial distress, market reorganization
- Study: Patient care experience declined after private equity hospital acquisitions
- Report: Medical student distress rises amid overall healthcare burnout improvement
- Prosthetic insurance coverage disparities persist despite legal protections
- Study: GLP-1 drugs reduce surgical complications in diabetes patients
- United Surgical Partners agrees to $1.48M settlement in 401(k) fee lawsuit
- Healthcare M&A activity set to rebound in 2025 amid stricter state oversight
- High participation in ASCQR program continues, March deadline for reconsideration requests
- Study: Preoperative stereotactic radiosurgery shows promise in brain metastases management
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement